Risk factors for schizophrenia - All roads lead to dopamine

European Neuropsychopharmacology

Volumn 17, Issue SUPPL. 2, 2007, Pages

  Di Forti, Marta ^a   Lappin, Julia M ^a   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine; Neurodevelopment; Schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE; DYSBINDIN; GENE PRODUCT; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; COGNITIVE DEFECT; COMT GENE; DAOA GENE; DISC1 GENE; DISEASE PREDISPOSITION; DOPAMINERGIC SYSTEM; DTNBP1 GENE; GENE; HUMAN; INCIDENCE; MIGRATION; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NEUROCHEMISTRY; NRG1 GENE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SYMPTOMATOLOGY; URBAN AREA;

BRAIN; DOPAMINE; HUMANS; RISK FACTORS; SCHIZOPHRENIA; SEX CHARACTERISTICS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 33847332514     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.02.005     Document Type: Article

References (51)

1. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., and Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 8104-8109
2. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325 (2002) 1212-1213
3. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184 (2004) 110-117
4. Berton O., McClung C.A., Dileone R.J., Krishnan V., Renthal W., Russo S.J., Graham D., Tsankova N.M., Bolanos C.A., Rios M., Monteggia L.M., Self D.W., and Nestler E.J. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311 (2006) 864-868
5. Blackwood D.H., Visscher P.M., and Muir W.J. Genetic studies of bipolar affective disorder in large families. Br. J. Psychiatr., Suppl. 41 (2001) s134-s136
6. Boksa P., and El-Khodor B.F. Birth insult interacts with stress at adulthood to alter dopaminergic function in animal models: possible implications for schizophrenia and other disorders. Neurosci. Biobehav. Rev. 27 (2003) 91-101
7. Boydell J., Van Os J., Lambri M., Castle D., Allardyce J., McCreadie R.G., and Murray R.M. Incidence of schizophrenia in south-east London between 1965 and 1997. Br. J. Psychiatry 182 (2003) 45-49
8. Boydell J., van Os J., Caspi A., Kennedy N., Giouroukou E., Fearon P., Farrell M., and Murray R.M. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol. Med. 36 (2006) 1441-1446
9. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., van der Linden J.A., Schothorst P.F., van Engeland H., and Kahn R.S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Arch. Gen. Psychiatry 59 (2002) 1002-1010
10. Cannon M., Jones P.B., and Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry 159 (2002) 1080-1092
11. Cantor-Graae E., and Selten J.P. Schizophrenia and migration: a meta-analysis and review. Am. J. Psychiatry 162 (2005) 12-24
12. Cardno A.G., Rijsdijk F.V., Sham P.C., Murray R.M., and McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am. J. Psychiatry 159 (2002) 539-545
13. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57 (2005) 1117-1127
14. Castle D.J., and Murray R.M. The neurodevelopmental basis of sex differences in schizophrenia. Psychol. Med. 21 (1991) 565-575
15. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh E.W., Hsiao C.C., Chiang Y.L., Ree S.C., Lee C.H., and Murray R.M. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol. Med. 33 (2003) 1407-1414
16. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh el W., and Murray R.M. Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis. Am. J. Med. Genet., B, Neuropsychiatr. Genet 136 (2005) 87-91
17. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J., and Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 30 (2005) 765-774
18. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., and Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6917-6922
19. Fearon P., Kirkbride J.B., Morgan C., Dazzan P., Morgan K., Lloyd T., Hutchinson G., Tarrant J., Fung W.L., Holloway J., Mallett R., Harrison G., Leff J., Jones P.B., and Murray R.M. Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychol. Med. 36 (2006) 1541-1550
20. Gilmore J. Prenatal and Perinatal Factors (2006), American Psychiatric Press, Washington, DC 71-85
21. Hall F.S., Wilkinson L.S., Humby T., and Robbins T.W. Maternal deprivation of neonatal rats produces enduring changes in dopamine function. Synapse 32 (1999) 37-43
22. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 (2003) 417-419
23. Henquet C., Murray R., Linszen D., and van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 31 (2005) 608-612
24. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., and van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31 (2006) 2748-2757
25. Hodgkinson C.A., Goldman D., Jaeger J., Persaud S., Kane J.M., Lipsky R.H., and Malhotra A.K. Disrupted in schizophrenia 1 (DISC1): association with schizophrenia, schizoaffective disorder, and bipolar disorder. Am. J. Hum. Genet. 75 (2004) 862-872
26. Job D.E., Whalley H.C., Johnstone E.C., and Lawrie S.M. Grey matter changes over time in high risk subjects developing schizophrenia. NeuroImage 25 (2005) 1023-1030
27. Kapur S., Mizrahi R., and Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 79 (2005) 59-68
28. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., and Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49 (2006) 603-615
29. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
30. Li T., Vallada H., Curtis D., Arranz M., Xu K., Cai G., Deng H., Liu J., Murray R., Liu X., and Collier D.A. Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics 7 (1997) 349-353
31. Li D., Collier D.A., and He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum. Mol. Genet. 15 (2006) 1995-2002
32. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., and Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005) 361-370
33. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 29 (2004) 282-286
34. McCormick L., Decker L., Nopoulos P., Ho B.C., and Andreasen N. Effects of atypical and typical neuroleptics on anterior cingulate volume in schizophrenia. Schizophr. Res. 80 (2005) 73-84
35. McGrath J.J. Variations in the incidence of schizophrenia: data versus dogma. Schizophr. Bull. 32 (2006) 195-197
36. Morgan D., Grant K.A., Gage H.D., Mach R.H., Kaplan J.R., Prioleau O., Nader S.H., Buchheimer N., Ehrenkaufer R.L., and Nader M.A. Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration. Nat. Neurosci. 5 (2002) 169-174
37. Morris D.W., McGhee K.A., Schwaiger S., Scully P., Quinn J., Meagher D., Waddington J.L., Gill M., and Corvin A.P. No evidence for association of the dysbindin gene [DTNBP1] with schizophrenia in an Irish population-based study. Schizophr. Res. 60 (2003) 167-172
38. Mortensen P.B., Pedersen C.B., Westergaard T., Wohlfahrt J., Ewald H., Mors O., Andersen P.K., and Melbye M. Effects of family history and place and season of birth on the risk of schizophrenia. N. Engl. J. Med. 340 (1999) 603-608
39. Munro C.A., McCaul M.E., Wong D.F., Oswald L.M., Zhou Y., Brasic J., Kuwabara H., Kumar A., Alexander M., Ye W., and Wand G.S. Sex differences in striatal dopamine release in healthy adults. Biol. Psychiatry 59 (2006) 966-974
40. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch. Gen. Psychiatry 56 (1999) 940-945
41. Nosarti C., Al-Asady M.H., Frangou S., Stewart A.L., Rifkin L., and Murray R.M. Adolescents who were born very preterm have decreased brain volumes. Brain 125 (2002) 1616-1623
42. Pantelis C., Velakoulis D., McGorry P.D., Wood S.J., Suckling J., Phillips L.J., Yung A.R., Bullmore E.T., Brewer W., Soulsby B., Desmond P., and McGuire P.K. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361 (2003) 281-288
43. Pedersen C.B., and Mortensen P.B. Evidence of a dose-response relationship between urbanicity during upbringing and schizophrenia risk. Arch. Gen. Psychiatry 58 (2001) 1039-1046
44. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., Albus M., Lerer B., Rietschel M., Trixler M., Maier W., and Wildenauer D.B. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72 (2003) 185-190
45. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., Premont R.T., Sotnikova T.D., Boksa P., El-Ghundi M., O'Dowd B., George F., Perreault S.R., Mannisto M.L., Robinson P.T., Palmiter S., and Tallerico R.D. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3513-3518
46. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., and Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002) 877-892
47. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., Harris-Kerr C., Wormley B., Sadek H., Kadambi B., Cesare A.J., Gibberman A., Wang X., O'Neill F.A., Walsh D., and Kendler K.S. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71 (2002) 337-348
48. Tosato S., Dazzan P., and Collier D. Association between the neuregulin 1 gene and schizophrenia: a systematic review. Schizophr. Bull. 31 (2005) 613-617
49. Velakoulis D., Wood S.J., Wong M.T., McGorry P.D., Yung A., Phillips L., Smith D., Brewer W., Proffitt T., Desmond P., and Pantelis C. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 63 (2006) 139-149
50. Williams N.M., Preece A., Morris D.W., Spurlock G., Bray N.J., Stephens M., Norton N., Williams H., Clement M., Dwyer S., Curran C., Wilkinson J., Moskvina V., Waddington J.L., Gill M., Corvin A.P., Zammit S., Kirov G., Owen M.J., and O'Donovan M.C. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch. Gen. Psychiatry 61 (2004) 336-344
51. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157 (2000) 16-25